Saturday, 25 July 2026

Indian corporate news, decoded into deal flow

DEAL FLOW
Paras Defence Amends Insider Trading and… ▲ Shareholding & Insider Moves Cybertech Systems Q1 FY27 Results: Revenue… ▲ Results Details Ganesh Housing Q1 FY27 Results: Revenue… ▲ Results Details Tata Consumer Products Reports 12% YoY… ▲ Results Details CG Power and Industrial Solutions Reports… ▲ Results Details DCB Bank Posts 35.57% PAT Growth… ▲ Results Details Cyient DLM Hits Record Order Book… ▲ Order Book
Home / Company Results / Taurus Labs Reports Q1 FY27 Revenue of ₹2,026 Crore, Up 29% YoY; EBITDA Margin Expands to 31.8%
RS · Company Results

Taurus Labs Reports Q1 FY27 Revenue of ₹2,026 Crore, Up 29% YoY; EBITDA Margin Expands to 31.8%

BY ADMIN • FILED 24 Jul 2026, 10:28 PM

Laurus Labs Limited released its investor presentation for the first quarter of FY27, reporting strong financial performance driven by robust growth in its Contract Development and Manufacturing Organization (CDMO) business and steady demand across its Affordable Medicines portfolio.

The company delivered healthy revenue growth, significant margin expansion, and continued investments in expanding its manufacturing capabilities across multiple high-value pharmaceutical platforms.

Laurus Labs Q1 FY27 Financial Highlights

Laurus Labs reported a strong operational performance during the quarter ended June 30, 2026:

  • Revenue from Operations: ₹2,026 crore, registering 29% year-on-year growth.
  • EBITDA: ₹644 crore.
  • EBITDA Margin: 31.8%, expanding by 700 basis points compared with Q1 FY26.
  • Gross Margin: 62.7%, improving by more than 330 basis points year-on-year, supported by a favourable product and business mix.

The strong improvement in profitability was driven by higher operating leverage and increased contribution from high-margin businesses.

CDMO Business Continues to Drive Growth

The company’s Contract Development and Manufacturing Organization (CDMO) segment remained the primary growth engine during the quarter.

Growth was supported by:

  • Strong commercial project supplies.
  • Increased execution across customer programs.
  • Higher contribution from value-added manufacturing services.
  • Continued expansion of long-term customer partnerships.

The Affordable Medicines business also maintained stable performance, providing a solid foundation for overall revenue growth.

Continued Investment in Future Growth

Laurus Labs continued to invest aggressively in expanding its manufacturing infrastructure and strengthening its capabilities across advanced pharmaceutical technologies.

Capital Expenditure Highlights

  • Q1 FY27 Capital Expenditure: ₹394 crore.
  • Capex as a Percentage of Revenue: Approximately 19% during the quarter.
  • FY22–FY27 Planned Capital Investment: More than ₹4,700 crore, representing around 16% of cumulative revenue.
  • Growth Allocation: Over 85% of the planned capital expenditure is dedicated to expansion and growth initiatives.

Focus Areas for Capacity Expansion

The company is expanding capabilities across several high-growth pharmaceutical segments, including:

  • Active Pharmaceutical Ingredients (APIs).
  • Finished Formulations.
  • Peptides.
  • Fermentation technologies.
  • Gene Therapy.
  • Antibody-Drug Conjugates (ADCs).

These investments are expected to strengthen Laurus Labs’ position in complex pharmaceuticals and high-value manufacturing services.